AzTrials
AzTrials

Breast CancerNCT07023198

Clinical Breast Examination and Patient Navigation Intervention in Sub-Saharan Africa

A study testing Clinical breast examination and Navigation in people with Breast Cancer, run by Addis Ababa University at 1 site in Ethiopia.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Brief summery Prolonged presentation, along with diagnostic and treatment delays, remain significant problems for breast cancer care in sub-Saharan Africa , primarily due to low health-seeking behaviour, lack of access, long waiting times, and weak referral systems. Read more about this study

Who is it for?
Ages 30 years and older, women onlyHealthy volunteers can take part
Conditions the study is for
Breast Cancer
What is being tested?
Clinical breast examination and Navigation
Could I receive a placebo?
No, everyone receives an active treatment
How many people
8,000 participants
Where
1 siteEthiopia
Study dates
24 Mar 2025to Mar 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 years and older
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • women who are within the age range recommended for breast cancer screening according to national guidelines in the participating countries and presenting to the study facilities, including attendants, women presenting for various health services, such as outpatient care, maternal and child health services, or other health needs
  • Women presented to the facilities with any breast abnormalities
  • Women with suspicious breast lesions who will be referred to the study facilities - women who are willing to undergo CBE following informed consent

Who cannot join

  • Women screened for breast cancer in the past year
  • Women who have been treated for breast cancer in the past year and males will be excluded

Trial locations and contacts

1 site in 1 country.

Ethiopia1 site
  • Primary and secondary health care facilities from four sub-Saharan African countries that make up the Network for Oncology Research in Africa (NORA) consortium: Ethiopia, South Africa, Nigeria, and Tanzania.

    Addis Ababa, Addis Ababa, 9086

Other trials in Ethiopia

About this study

Official title: Provider-Initiated Screening Clinical Breast Examination and Patient Navigation in Sub-Saharan Africa

Brief summery Prolonged presentation, along with diagnostic and treatment delays, remain significant problems for breast cancer care in sub-Saharan Africa , primarily due to low health-seeking behaviour, lack of access, long waiting times, and weak referral systems. Despite these challenges, evidence-based interventions like structured breast screening and patient navigation services are limited. To address these issues, the investigators aimed to implement a provider-initiated clinical breast examination and patient navigation intervention using an implementation mapping approach.

This is just a pragmatic implementation pilot study in the four sub-Saharan African countries that make up the Network for Oncology Research in Africa (NORA) consortium: Ethiopia, South Africa, Nigeria, and Tanzania after identifying contextual barriers and implementation determinants using a baseline assessment. The main aim of the study is to improve timely diagnosis and initiation of breast cancer treatment by implementing provider-initiated clinical breast examination and patient navigation interventions.

The study has the following key outcomes: Proportion of CBE uptake, time to diagnosis, proportion of early-stage disease, time to treatment initiation, barriers to implementation, adoption by providers and implementation fidelity The study will strictly follow the steps of implementation mapping design to select and evaluate implementation strategies to bring an evidence-based intervention. In addition, the study will apply established frameworks such as the CFIR and RE-AIM, which can strengthen the study's ability to identify, measure, and interpret multiple implementation outcomes. This study aligns with the Ministry of Health priorities of each individual countries aimed at scaling up breast cancer early detection in primary and secondary level health care settings. Therefore, it will provide evidence-based strategies that can be incorporated into the routine health care practice to address multiple points of delay in the care pathway, mainly in the early detection and referral phases at each level of the health care system. The findings will offer a promising strategy to address critical delays in the breast cancer care continuum for low \& middle income settings facing similar challenges. Moreover, the findings will contribute to national and global efforts to improve breast cancer care equity and outcomes through implementation science.

Read the detailed description

The majority of breast cancer patients experienced long delays from their initial presentation to final diagnosis and treatment initiation in sub-Saharan Africa , primarily due to low health-seeking behavior, lack of access, long waiting times for diagnostic workups, and weak referral systems. Despite these challenges, evidence-based interventions like structured breast screening using clinical breast exams and PN services are limited. CBE is offered only for those presenting with breast complaints. Standard screening tools such as mammography are very limited in the settings. This urges an urgent need for context-specific implementation strategies that are evidence-based and feasible within the constraints of the health care facilities in the countries, where patients suffer long diagnostic and treatment delays.

The investigators hypothesized that implementing provider-initiated (CBE) and PN would improve the screening uptake, timely diagnosis, and linkage to treatment for breast cancer in the region. The intervention will be implemented based on the national breast health guideline of each individual countries, which recommends using CBE and PN services with effective referral pathways. This combined approach aligns with the WHO's global breast cancer initiative (GBCI), aiming to reduce mortality through early detection and comprehensive care, and is particularly suited to low and middle income countries .

The investigators aimed to use the Implementation Mapping framework, a systematic, step-by-step methodology used to guide the development of implementation strategies that enhance the adoption, execution, and sustainability of evidence-based interventions by engaging stakeholders within local settings. This study will address a critical gap in breast cancer care by facilitating early detection, timely diagnosis, and care. Moreover, the findings will generate practical insights and scalable approaches that can inform policymakers and be expanded nationally by integrating them into the conventional healthcare system and tailoring them for other low-resource settings facing comparable issues.

Implementation process Our implementation will follow the following five steps of implementation mapping design Step 1: Conduct a needs assessment The first step is conducting a thorough assessment using the CFIR framework to gather general information on the health care infrastructure and workforce, opportunities, and challenges from the perspectives of stakeholders by conducting initial health facility surveys, IDIs, and FGDs.

Step 2: Identify adoption and implementation outcomes, performance objectives, performance determinants, and change objectives In this step, the investigators will identify the potential adoption and implementation outcomes, performance objectives, performance determinants, and change objectives based on our formative assessment findings Step 3: Select and Design Implementation Strategies

In the third step, the investigators identified the following key implementation strategies that address the specific needs of receivers and implementers within the local context:

  1. Training healthcare providers in CBE and PN; the investigators will provide comprehensive training for HCPs on CBE and PN using practical demonstrations and role-playing scenarios to enhance their knowledge and skills.
  2. Integrating the initiative into routine clinical workflows: the clinical staff working in the hospitals will be oriented to link eligible women to navigators\& those who present with breast complaints to the trained breast nurses for CBE \& navigation service. We will make all the eligibility criteria and educational materials accessible to all clinical staff and ensure that the initiative becomes a routine part of care.
  3. Provider engagement and incentives; Incentive mechanisms that encourage participation in training and the adoption of CBE \& PN practices will be developed. This includes recognition awards, professional development opportunities, and financial incentives based on performance metrics.
  4. Community engagement and awareness; the investigators will develop awareness creation programs within the hospitals (Morning health education in waiting areas) and community settings using posters, brochures, and social media to educate the public about the importance of breast cancer screening and early detection. Breast cancer survivors, community HEWs, and key informants will be involved to advocate for breast health and screening.
  5. Intervention delivery: The navigators will identify eligible women for CBE on each day among the facility attendants and invite them to undergo a CBE screening. Clinical staff will also identify eligible women from their daily contacts and advice, and link women to the trained nurse for CBE screening. The screening will be held every day at each site. A screening card will be given to the screened women with the date of last screening and the date when the next screening will be. The navigators will have direct communication with clinical staff daily. Navigators will contact referred patients by phone within 2 days of referral, collect baseline data, provide counselling on follow-up and undergoing further evaluation, give date for follow-up within 14 days of referral, send SMS reminder to patient 3 and 1 days before scheduled follow-up, follow-up on whether patient presented for first evaluation at diagnostic center, follow-up 45 days post-referral to check whether patient has completed all recommended testing, keep records of patients' progress until evaluation of breast (confirmed diagnosis) is complete. The navigator will have communications with the referral center to assist her until she finishes all the diagnoses. Local community HEWs will be used to trace women in case access by phone is difficult. The Redcap database will be used to track patient progress and to generate reports that support navigators' and screener's workflow.
  6. Monitoring and Feedback: A structured follow-up tool will be developed to track key performance indicators (KPIs) such as the number of CBEs performed, referrals made, and time to diagnosis recorded through the RedCap database. The supervisory team will hold weekly meetings with the providers and monthly onsite supervisions to monitor the progress and ensure adherence to the protocol. Daily feedback will be provided to providers on their performance to encourage continuous improvement.
  7. Collaboration with stakeholders; stakeholders at local and national levels, including the regional and MOH officials, local NGOs, hospital leaders, patients, HEWs, and research and academic institutions, will be involved.
  8. Addressing barriers to care; a dedicated healthcare professional (trained breast nurses) will be assigned to identify barriers and to guide patients through the healthcare system
  9. Sustainability planning; the intervention is being implemented according to the newly launched national breast health guideline recommendations. Ongoing training and support for providers will be planned for the long-term integration of the intervention into routine practice.

Step 4: Produce Implementation Protocols and Materials. In this step, a set of necessary protocols \& materials will be developed. This includes health education materials (audio visuals, posters, brochures), follow-up data collection tools, registration log books, screening tickets, HCP training manuals, CBE and PN SOPs, consent forms, patient navigation tracking forms, referral logbooks, post-intervention assessment tools, observation checklists, monitoring and evaluation tools.

Step 5: Evaluation of implementation outcomes In this step, a RE-AIM framework will be used to evaluate the impact of the intervention on improving each of the adoption and implementation outcomes. Surveys and interviews will be conducted with HCPs and patients to understand their perceptions and experiences with the intervention using each domain of the RE-AIM framework.

Conditions
Breast Cancer
Being tested
Clinical breast examination and Navigation
Keywords
breast cancer screening, Patient navigation, implementation research, Ethiopia
Medical subject headings
Breast Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Clinical breast examination and NavigationOther

    trained nurses on clinical breast examination and navigation will provide screening for all eligible women and they will follow those women who will have suspicious breast lesions until they have completed their final diagnosis of breast cancer and initiation of breast cancer treatment

Study groups in NCT07023198
Study groupRoleWhat they receive
Clinical breast examination and navigationExperimentalNurses will be trained on clinical breast examination techniques and navigation to routinely offer CBE to eligible women and to support women with suspicious findings until compilation of diagnosis and Initiation of breast cancer treatment
Receives: Other: Clinical breast examination and Navigation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time to diagnosis of a suspicious breast lesion

    Time from first presentation to confirmed diagnosis of suspicious breast lesion. If < 60 days, it is considered a short interval and if ≥ 60 days, it is considered as long interval

    Measured: 12 month

  2. Proportion of clinical breast examination (CBE) uptake

    This the percentage of women who undergo CBE from the total eligible women who come to the study hospitals each working day

    Measured: 12 month

Secondary outcomes (2)
  1. proportion of early stage diagnosis among suspecious breast lesions

    This is the proportion of early-stage disease among total suspicious breast lesions identified. Tumors will be categorized according to the American Joint Committee on Cancer staging manual, 7th edition. All clinical, investigative, and intraoperative findings will be used to stage the disease. Stage 1 (T1N0); stage 2 (IIA=T0N1, T1N1 \&T2N0, IIB= T2N1\& T3N0,) and stage 3 (IIIA=T0N2, T1N2, T2N2, T3N1\&T3N2, IIIB=T4N0, T4N1, T4N2, IIIC= Any T N3) and stage 4 (any T any N and M1). Stage III and IV disease will be defined as 'late stages', and stage I and II disease will be defined as 'early stage' disease

    Measured: 12 month

  2. Time to treatment initiation

    The time from pathological diagnosis to initiation of the first breast cancer treatment if < 30 days, it is considered as short interval and if ≥30 days, it is considered as long interval

    Measured: 12 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Jun 2025
  2. Study start24 Mar 2025
  3. Primary completion24 Mar 2026 (estimated)
  4. Study completionMar 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Model description
An implementation mapping based pilot study will be conducted which is a process framework that provides a systematic, five-step approach to select and evaluate implementation strategies to bring an evidence-based intervention. This design includes: 1) conducting a needs assessment, (2) identify adoption and implementation outcomes, performance objectives, performance determinants, and change objectives), (3) select \& design implementation strategies, (4) produce implementation protocols and materials and (5) evaluate implementation outcomes (1). The RE-AIM framework will also be used to evaluate the implementation process and outcome. It is a comprehensive model designed to evaluate and enhance the impact of health interventions, by considering individual and organizational factors that influence the success of health interventions
Masking
None (open label)
Enrolment
8,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07023198
Sponsor's protocol ID
SPH 034/24/SPH, MLU 2025-123
Other IDs
(BMFTR) 01KA2220B, Del-22-008
Status last verified
Mar 2026
First submitted
5 Jun 2025
Last updated
1 Apr 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The data for this study will be shared based on a reasonable request to the principal investigator of the study

Publications

  • Pace LE, Dusengimana JV, Keating NL, Hategekimana V, Rugema V, Bigirimana JB, Costas-Chavarri A, Umwizera A, Park PH, Shulman LN, Mpunga T. Impact of Breast Cancer Early Detection Training on Rwandan Health Workers' Knowledge and Skills. J Glob Oncol. 2018 Sep;4:1-10. doi: 10.1200/JGO.17.00098.

    PubMed 30241228
  • Hoffman HJ, LaVerda NL, Young HA, Levine PH, Alexander LM, Brem R, Caicedo L, Eng-Wong J, Frederick W, Funderburk W, Huerta E, Swain S, Patierno SR. Patient navigation significantly reduces delays in breast cancer diagnosis in the District of Columbia. Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1655-63. doi: 10.1158/1055-9965.EPI-12-0479.

    PubMed 23045540
  • Rabe F, Getachew S, Stroetmann CY, Mezger NCS, Gebremariam TY, Berhane B, Mremi A, Mmbaga BT, Boucheron P, McCormack V, Santos P, Addissie A, Kantelhardt EJ. Time to pathologic diagnosis of suspicious breast lesions: An institution-based study in five Ethiopian hospitals. Int J Cancer. 2025 Sep 1;157(5):876-889. doi: 10.1002/ijc.35436. Epub 2025 Apr 10.

    PubMed 40207740
  • Rohsig V, Silva P, Teixeira R, Lorenzini E, Maestri R, Saraiva T, Souza A. Nurse Navigation Program: Outcomes From a Breast Cancer Center in Brazil. Clin J Oncol Nurs. 2019 Feb 1;23(1):E25-E31. doi: 10.1188/19.CJON.E25-E31.

    PubMed 30682003
  • Khanna AS, Brickman B, Cronin M, Bergeron NQ, Scheel JR, Hibdon J, Calhoun EA, Watson KS, Strayhorn SM, Molina Y. Patient Navigation Can Improve Breast Cancer Outcomes among African American Women in Chicago: Insights from a Modeling Study. J Urban Health. 2022 Oct;99(5):813-828. doi: 10.1007/s11524-022-00669-9. Epub 2022 Aug 8.

    PubMed 35941401
  • Sankaranarayanan R, Ramadas K, Thara S, Muwonge R, Prabhakar J, Augustine P, Venugopal M, Anju G, Mathew BS. Clinical breast examination: preliminary results from a cluster randomized controlled trial in India. J Natl Cancer Inst. 2011 Oct 5;103(19):1476-80. doi: 10.1093/jnci/djr304. Epub 2011 Aug 23.

    PubMed 21862730
  • Provencher L, Hogue JC, Desbiens C, Poirier B, Poirier E, Boudreau D, Joyal M, Diorio C, Duchesne N, Chiquette J. Is clinical breast examination important for breast cancer detection? Curr Oncol. 2016 Aug;23(4):e332-9. doi: 10.3747/co.23.2881. Epub 2016 Aug 12.

    PubMed 27536182
  • Fuller MS, Lee CI, Elmore JG. Breast cancer screening: an evidence-based update. Med Clin North Am. 2015 May;99(3):451-68. doi: 10.1016/j.mcna.2015.01.002. Epub 2015 Mar 5.

    PubMed 25841594
  • Anderson BO, Ilbawi AM, Fidarova E, Weiderpass E, Stevens L, Abdel-Wahab M, Mikkelsen B. The Global Breast Cancer Initiative: a strategic collaboration to strengthen health care for non-communicable diseases. Lancet Oncol. 2021 May;22(5):578-581. doi: 10.1016/S1470-2045(21)00071-1. Epub 2021 Mar 7. No abstract available.

    PubMed 33691141
  • Dye TD, Bogale S, Hobden C, Tilahun Y, Hechter V, Deressa T, Bize M, Reeler A. Complex care systems in developing countries: breast cancer patient navigation in Ethiopia. Cancer. 2010 Feb 1;116(3):577-85. doi: 10.1002/cncr.24776.

    PubMed 20029968
  • Trabitzsch J, Wondimagegnehu A, Afework T, Stoeter O, Gizaw M, Getachew S, Feyisa JD, Taylor L, Wienke A, Addissie A, Kantelhardt EJ. Pathways and Referral of Patients with Cancer in Rural Ethiopia: A Multi-center Retrospective Cohort Study. Oncologist. 2023 Jun 2;28(6):e359-e368. doi: 10.1093/oncolo/oyad032.

    PubMed 36940294
  • Shita A, Yalew AW, Seife E, Afework T, Tesfaw A, Gufue ZH, Rabe F, Taylor L, Kantelhardt EJ, Getachew S. Survival and predictors of breast cancer mortality in South Ethiopia: A retrospective cohort study. PLoS One. 2023 Mar 6;18(3):e0282746. doi: 10.1371/journal.pone.0282746. eCollection 2023.

    PubMed 36877683
  • Tesfaw A, Getachew S, Addissie A, Jemal A, Wienke A, Taylor L, Kantelhardt EJ. Late-Stage Diagnosis and Associated Factors Among Breast Cancer Patients in South and Southwest Ethiopia: A Multicenter Study. Clin Breast Cancer. 2021 Feb;21(1):e112-e119. doi: 10.1016/j.clbc.2020.08.011. Epub 2020 Oct 1.

    PubMed 33536135
  • Joko-Fru WY, Miranda-Filho A, Soerjomataram I, Egue M, Akele-Akpo MT, N'da G, Assefa M, Buziba N, Korir A, Kamate B, Traore C, Manraj S, Lorenzoni C, Carrilho C, Hansen R, Finesse A, Somdyala N, Wabinga H, Chingonzoh T, Borok M, Chokunonga E, Liu B, Kantelhardt E, McGale P, Parkin DM. Breast cancer survival in sub-Saharan Africa by age, stage at diagnosis and human development index: A population-based registry study. Int J Cancer. 2020 Mar 1;146(5):1208-1218. doi: 10.1002/ijc.32406. Epub 2019 Jun 14.

    PubMed 31087650
  • Geremew H, Golla EB, Simegn MB, Abate A, Ali MA, Kumbi H, Wondie SG, Mengstie MA, Tilahun WM. Late-stage diagnosis: The driving force behind high breast cancer mortality in Ethiopia: A systematic review and meta-analysis. PLoS One. 2024 Jul 19;19(7):e0307283. doi: 10.1371/journal.pone.0307283. eCollection 2024.

    PubMed 39028722

Questions about this trial

What is this clinical trial studying?

A study testing Clinical breast examination and Navigation in people with Breast Cancer, run by Addis Ababa University at 1 site in Ethiopia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 1 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Ethiopia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time to diagnosis of a suspicious breast lesion (time frame: 12 month). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07023198, which also lists 16 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2026; AzTrials last refreshed its copy on 26 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in